Development and Validation of Limited Sampling Strategies for the Estimation of Mycophenolic Acid Area Under the Curve in Adult Kidney and Liver Transplant Recipients Receiving Concomitant Enteric-Coated Mycophenolate Sodium and Tacrolimus

被引:24
作者
Pawinski, Tomasz [1 ]
Luszczynska, Paulina [1 ]
Durlik, Magdalena [2 ]
Majchrzak, Jadwiga [2 ]
Baczkowska, Teresa [2 ]
Chrzanowska, Maria [3 ]
Sobiak, Joanna [3 ]
Glyda, Maciej [4 ]
Kuriata-Kordek, Magdalena [5 ]
Kaminska, Dorota [5 ]
Krajewska, Magdalena [5 ]
Klinger, Marian [5 ]
机构
[1] Med Univ Warsaw, Dept Drug Chem, Fac Pharm, PL-02097 Warsaw, Poland
[2] Inst Transplantat, Dept Transplantat Med & Nephrol, Warsaw, Poland
[3] Univ Med Sci, Dept Phys Pharm & Pharmacokinet, Poznan, Poland
[4] Dist Hosp, Dept Transplantat & Gen Surg, Poznan, Poland
[5] Med Univ, Dept Nephrol & Transplantat Med, Wroclaw, Poland
关键词
mycophenolic acid; tacrolimus; mycophenolate sodium; limited sampling strategy; pharmacokinetics; renal and liver transplantation; SOLID-ORGAN TRANSPLANTATION; MOFETIL; PHARMACOKINETICS; CYCLOSPORINE; EXPOSURE; PHARMACODYNAMICS; BIOEQUIVALENCE; FORMULATION;
D O I
10.1097/FTD.0b013e31829b88f5
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Mycophenolic acid (MPA) is widely used in solid organ transplantation. MPA absorption from enteric-coated mycophenolate sodium (EC-MPS) is delayed, which results in a delayed enterohepatic recirculation and subsequently higher and more variable MPA 12-hour trough concentration and t(max) values. Therefore, MPA trough level monitoring cannot be used to monitor MPA exposure in patients who are given EC-MPS. The aim of the study was to develop and validate a limited sampling strategy (LSS) for accurate prediction of the 12-hour area under the concentration-time curve (AUC(0-12h)) for MPA in patients who receive concomitant EC-MPS and Tacrolimus (Prograf or Advagraf) within 196 months posttransplantation. According to our knowledge, the LSS for MPA AUC estimation using high-performance liquid chromatography to determine MPA concentrations in plasma samples of kidney and liver transplant patients receiving EC-MPS and Tacrolimus (Advagraf) has not been previously evaluated.Methods:Seventy-four renal and liver transplant patients receiving EC-MPS and concomitant tacrolimus (either Prograf or Advagraf) provided a total of 74 pharmacokinetic profiles. MPA concentrations were measured using a validated high-performance liquid chromatography method for 9 plasma samples collected at predose and at 0.5, 1, 2, 3, 4, 6, 9, and 12 hours after the morning dose of EC-MPS after an overnight fast. LSS were developed and validated by stepwise multiple regression analysis with the use of a 2-group method (test, n = 37; and validation, n = 37).Results:The 3 and 4 time point equations using C-1h, C-3h, C-9h and C-1h, C-2h, C-3h, C-6h, respectively, were found to be superior to all other models tested. When these LSS models were tested in the validation group, the results were acceptable [for 3 time points equation: r(2) = 0.824, percentage of prediction error: 6.32 25.75, 95% confidence interval (CI): -40.71 to 79.76; percentage of absolute prediction error: 27.45 +/- 29.89, 95% CI: 0.04-199.92, predictive performance, 71% of estimated AUCs comprised within 85%-115% of the measured full MPA AUC, natural logarithmic residuals (ln) mean +/- SD: -0.03 +/- 0.24; for 4 time points equation: r(2) = 0.898, percentage of prediction error: 3.32 +/- 18.26, 95% CI: -49.35 to 51.06; percentage of absolute prediction error: 14.05 +/- 11.89, 95% CI 0.13-49.86, percentage of predictive performance, 83% of estimated AUCs comprised within 85%-115% of the measured full MPA AUC, natural logarithmic residuals (ln) mean +/- SD: -0.01 +/- 0.19].Conclusions:LSS equations using concentrations at 1, 3, and 9 hours or 1, 2, 3, and 6 hours time points provided the most reliable and accurate estimations of the MPA AUC in stable renal and liver transplant recipients treated with EC-MPS and tacrolimus. Further studies on independent groups of patients are required to confirm clinical utility of the presented LSS models.
引用
收藏
页码:760 / 769
页数:10
相关论文
共 28 条
[1]   Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil [J].
Arns, W ;
Breuer, S ;
Choudhury, S ;
Taccard, G ;
Lee, J ;
Binder, V ;
Roettele, J ;
Schmouder, R .
CLINICAL TRANSPLANTATION, 2005, 19 (02) :199-206
[2]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[3]   Evaluation of bioequivalence of highly variable drugs and drug products [J].
Budde, K. ;
Bauer, S. ;
Hambach, P. ;
Hahn, U. ;
Roeblitz, H. R. ;
Mai, I. ;
Diekmann, F. ;
Neumayer, H. -H. ;
Glander, P. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (04) :888-898
[4]   Enteric-coated mycophenolate sodium provides higher mycophenolic acid predose levels compared with mycophenolate mofetil: Implications for therapeutic drug monitoring [J].
Budde, Klemens ;
Tedesco-Silva, Helio ;
Pestana, Jose Medina ;
Glander, Petra ;
Neumayer, Hans-H. ;
Felipe, Claudia Rosso ;
Machado, Paula Pinheiro ;
Sechaud, Romain ;
Schmouder, Robert .
THERAPEUTIC DRUG MONITORING, 2007, 29 (03) :381-384
[5]   Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus:: Clinical, pharmacokinetic, and pharmacodynamic outcomes [J].
Budde, Klemens ;
Glander, Petra ;
Kraemer, Bernhard K. ;
Fischer, Wolfgang ;
Hoffmann, Ute ;
Bauer, Steffen ;
Grohmann, Jana ;
Neumayer, Hans-Hellmut ;
Arns, Wolfgang .
TRANSPLANTATION, 2007, 83 (04) :417-424
[6]   Evalutation of mycophenolic acid systemic exposure by limited sampling strategy in kidney transplant recipients receiving enteric-coated mycophenolate sodium (EC-MPS) and cyclosporine [J].
Capone, Domenico ;
Tarantino, Giovanni ;
Kadilli, Irket ;
Polichetti, Giuliano ;
Basile, Vincenzo ;
Federico, Stefano ;
Sabbatini, Massimo .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (09) :3019-3025
[7]   Pharmacokinetics of mycophenolate sodium and comparison with the mofetil transplant recipients formulation in stable kidney [J].
Cattaneo, Dario ;
Cortinovis, Monica ;
Baldelli, Sara ;
Bitto, Alessandra ;
Gotti, Eliana ;
Remuzzi, Giuseppe ;
Perico, Norberto .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (06) :1147-1155
[8]   Mycophenolate mofetil for solid organ transplantation: Does the evidence support the need for clinical pharmacokinetic monitoring? [J].
Cox, VC ;
Ensom, MHH .
THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :137-157
[9]   New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation [J].
de Jonge, Hylke ;
Naesens, Maarten ;
Kuypers, Dirk R. J. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (04) :416-435
[10]   Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium [J].
de Winter, Brenda C. M. ;
van Gelder, Teun ;
Mathot, Ron A. A. ;
Glander, Petra ;
Tedesco-Silva, Helio ;
Hilbrands, Luuk ;
Budde, Klemens ;
van Hest, Reinier M. .
THERAPEUTIC DRUG MONITORING, 2009, 31 (05) :585-591